IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Bockxmeer, F. M.
Right arrow Articles by Constable, I. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Bockxmeer, F. M.
Right arrow Articles by Constable, I. J.

Investigative Ophthalmology & Visual Science, Vol 26, 1140-1147, Copyright © 1985 by Association for Research in Vision and Ophthalmology

ARTICLES AND REPORTS

Taxol for the treatment of proliferative vitreoretinopathy

FM van Bockxmeer, CE Martin, DE Thompson and IJ Constable

Proliferative vitreoretinopathy (PVR) results in retinal detachment and visual impairment due to fibroblastic proliferation in the vitreous and subsequent cellular contraction. The authors have used an in vitro model for PVR to evaluate the action of the antineoplastic drug, taxol, on chorioretinal fibroblast proliferation and contractility. Dose response curves obtained show taxol to be a potent inhibitor of both cellular events. Fifty percent inhibition of contraction and proliferation occurred at 2 X 10(-8)M and 3 X 10(-9)M, respectively. On the basis of this pharmacodynamic data, three dosage regimes were chosen to evaluate possible prevention of PVR in an animal model based on the intravitreal injection of cultured fibroblasts. These animals trials show that a single intravitreal dose of either 35 micrograms or 0.5 microgram taxol significantly reduces incidence and extent of PVR. The average grade of vitreoretinal traction at 28 days for 35 micrograms taxol and 250,000 cells was 0.4 (control 1.8); for 35 micrograms taxol and 700,000 cells, 1.0 (control 2.2); and for 0.5 microgram taxol and 250,000 cells, 1.0 (control 2.3). Delayed optic nerve damage was noted with the highest dose used, but a good therapeutic margin may exist. Long-term clinical histopathologic and electrophysiologic studies will be required. The authors conclude from these preliminary studies that taxol holds definite promise for the relief of traction retinal detachment and PVR.


This article has been cited by other articles:


Home page
 IOVSHome page
H.-K. Choung, S.-E. Jin, M. J. Lee, C.-K. Kim, and J.-M. Hwang
Slow-Releasing Paclitaxel in Polytetrafluoroethylene/Polylactide-co-glycolide Laminate Delays Adjustment after Strabismus Surgery in Rabbit Model
Invest. Ophthalmol. Vis. Sci., December 1, 2008; 49(12): 5340 - 5345.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
J. J. Lee, J. K. Park, Y.-T. Kim, B.-M. Kwon, S. G. Kang, Y. D. Yoo, Y. S. Yu, and H. Chung
Effect of 2'-Benzoyl-oxycinnamaldehyde on RPE Cells In Vitro and in an Experimental Proliferative Vitreoretinopathy Model
Invest. Ophthalmol. Vis. Sci., September 1, 2002; 43(9): 3117 - 3124.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the Association for Research in Vision and Ophthalmology